论文部分内容阅读
他曾在音乐学院留学声乐,却考入美国哈佛大学和麻省理工学院,成为第一位获哈佛大学医学博士并入选完成哈佛临床住院及专家医师训练的中国人。第一个直接入选美国内科学院院士的来自中国的华人,并入选美国顶尖医师录。第一个在本世纪初出任美国医药与生物技术上市公司全面主管研发的华人执行官。他是拥有230多项国际专利与专利申请的研发科学家与发明家,带领团队成功研制出国际第一个癌转移基因靶向药物,世界第一个癌干细胞靶向药物(该药被美国评为全球2012十大癌症药物之首)等多项国际获奖创新成果。在国际金融危机的5年,他却带领团队将580万美元的科技公司建造成26.3亿美元的癌症干细胞领域的国际龙头企业,
He studied vocal music at the Conservatory of Music but was admitted to Harvard and MIT in the United States and became the first Chinese to receive a Harvard MD and was selected to complete Harvard clinical inpatient and specialist physician training. The first Chinese directly enrolled in the Chinese Academy of Medical Sciences from China and selected the top US physicians. The first was the Chinese executive in charge of R & D at the head of an American pharmaceutical and biotech company at the beginning of this century. He is a R & D scientist and inventor with more than 230 international patents and patent applications. He led the team to successfully develop the world’s first cancer metastatic gene targeting drug and the world’s first cancer stem cell targeting drug (which was rated by the United States as The world’s top ten cancer drugs in 2012) and many other international award-winning innovations. In the five years since the international financial crisis, he has led the team to build a $ 5.8 million technology company into a $ 2.63 billion international leader in cancer stem cells,